These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22736751)

  • 1. Natural, innate improvements in multiple sclerosis disability.
    Tremlett H; Zhu F; Petkau J; Oger J; Zhao Y;
    Mult Scler; 2012 Oct; 18(10):1412-21. PubMed ID: 22736751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).
    Shirani A; Zhao Y; Kingwell E; Rieckmann P; Tremlett H
    Mult Scler; 2012 Apr; 18(4):442-50. PubMed ID: 21952097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
    Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.
    Alroughani R; Ashkanani A; Lamdhade S
    Int J Neurosci; 2012 Feb; 122(2):82-7. PubMed ID: 21985585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of birth and disease progression in multiple sclerosis.
    Koch M; De Keyser J; Tremlett H
    Mult Scler; 2008 Jul; 14(6):793-8. PubMed ID: 18573829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study.
    Zhang T; Kingwell E; Zhu F; Petkau J; Kastrukoff LF; Marrie RA; Tremlett H; Evans C
    BMJ Open; 2017 Sep; 7(9):e018612. PubMed ID: 28965103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
    Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
    Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of long-term disability in multiple sclerosis.
    Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P
    Mult Scler; 2012 Jan; 18(1):31-8. PubMed ID: 21868486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.